RxDoctor Payments Data

Johnny Gayton, MD

Ophthalmology · Warner Robins, GANPI 1144224627

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.9%. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,692in general payments, 2019–2025

Across 333 payments — averaging $65.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beaver-visitec International, Inc.$5K
  • Alcon Research LLC$2K
  • AbbVie$2K
  • Alcon$2K
  • Shire North American Group Inc$2K
  • Bausch & Lomb Americas Inc.$2K
  • plus $8K from 27 others

What the payments were for

  • Consulting fees$7,65035%
  • Speaking & faculty fees$3,62517%
  • Travel & lodging$8454%
  • Food & beverage$9,50944%
  • Education$180%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,692 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$556,427
Medicare patients
1,114
Services billed
3,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac413$155,851
ProlensaBromfenac Sodium128$45,976
LumiganBimatoprost83$38,405
RestasisCyclosporine25$34,105
Prednisolone Acetate845$31,919
RhopressaNetarsudil Mesylate52$24,217
Bromfenac Sodium171$19,674
CombiganBrimonidine Tartrate/Timolol44$13,259
VyzultaLatanoprostene Bunod23$8,509
RocklatanNetarsudil Mesylat/Latanoprost16$7,923
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$6,900
SimbrinzaBrinzolamide/Brimonidine Tart29$5,625
Brimonidine Tartrate78$4,620
Cyclosporine19$4,383
Alphagan PBrimonidine Tartrate20$4,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$173$155,851413 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,776$90,126172 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$648$48,126140 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$91$32,14068 claims
Bausch & Lomb Americas Inc.Vyzulta$1,508$8,50923 claims
AlconSimbrinza$1,625$5,62529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →